Javascript must be enabled to continue!
Fatigue management in patients with IBD: a randomised controlled trial
View through CrossRef
Objective
To assess the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD).
Design
Randomised controlled trial in two Dutch hospitals. Patients with IBD with quiescent IBD and with a Checklist Individual Strength—Fatigue (CIS—fatigue) score of ≥35 were enrolled. Patients were 1:1 randomised to receive SFT or care as usual (CAU) for 3 months. Patients were followed for a further 6 months after the SFT. Primary endpoint was defined as changes in fatigue and QoL during follow-up. Secondary endpoints included change in anxiety and depression, medication use, side effects to medication, disease activity, laboratory parameters (C-reactive protein, leucocytes and haemoglobin) and sleep quality.
Results
Ninety-eight patients were included, of whom 63% were women, mean age was 40.1 years. After the SFT course, 17 (39%) patients in the SFT group had a CIS-fatigue score below 35 compared with eight (18%) of patients in the CAU group (p=0.03). The SFT group also showed a greater reduction in fatigue across the first 6 months compared with the CAU group (CIS-fatigue: p=<0.001 and CIS-total: p=0.001).
SFT was associated with a significant higher mean IBD questionnaire change at 3 months (p=0.020). At 9 months, no significant differences between the two groups were observed.
Conclusions
SFT has a significant beneficial effect on the severity of fatigue and QoL in patients with quiescent IBD. However, this effect diminished during follow-up.
Title: Fatigue management in patients with IBD: a randomised controlled trial
Description:
Objective
To assess the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD).
Design
Randomised controlled trial in two Dutch hospitals.
Patients with IBD with quiescent IBD and with a Checklist Individual Strength—Fatigue (CIS—fatigue) score of ≥35 were enrolled.
Patients were 1:1 randomised to receive SFT or care as usual (CAU) for 3 months.
Patients were followed for a further 6 months after the SFT.
Primary endpoint was defined as changes in fatigue and QoL during follow-up.
Secondary endpoints included change in anxiety and depression, medication use, side effects to medication, disease activity, laboratory parameters (C-reactive protein, leucocytes and haemoglobin) and sleep quality.
Results
Ninety-eight patients were included, of whom 63% were women, mean age was 40.
1 years.
After the SFT course, 17 (39%) patients in the SFT group had a CIS-fatigue score below 35 compared with eight (18%) of patients in the CAU group (p=0.
03).
The SFT group also showed a greater reduction in fatigue across the first 6 months compared with the CAU group (CIS-fatigue: p=<0.
001 and CIS-total: p=0.
001).
SFT was associated with a significant higher mean IBD questionnaire change at 3 months (p=0.
020).
At 9 months, no significant differences between the two groups were observed.
Conclusions
SFT has a significant beneficial effect on the severity of fatigue and QoL in patients with quiescent IBD.
However, this effect diminished during follow-up.
Related Results
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
Abstract
IBD, including ulcerative colitis and Crohn’s disease, is a chronic and debilitating gastrointestinal disorder that affects millions of people worldwide. Re...
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
Abstract
Background
Both inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are inflammatory diseases but there wa...
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
e15669
Background:
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition chara...
Serum neutrophil gelatinase associated lipocalin (NGAL) as a marker of activity in inflammatory bowel disease
Serum neutrophil gelatinase associated lipocalin (NGAL) as a marker of activity in inflammatory bowel disease
Abstract
Inflammatory bowel disease (IBD) is a disease of activity and remission. Lipocalin 2 (LCN2), the coding gene for NGAL is one of the most over-expressed genes in th...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
P579 Dietary beliefs, barriers, and acceptability of diet in IBD patients – a multi-centre survey from the Asia-Pacific region
P579 Dietary beliefs, barriers, and acceptability of diet in IBD patients – a multi-centre survey from the Asia-Pacific region
Abstract
Background
Dietary beliefs and behaviors in IBD patients may affect both clinical outcome and psychosocial aspect of pa...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...

